Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma
Nicole Concin, Xavier Matías‐Guiu, Ignace Vergote, et al.
International Journal of Gynecological Cancer (2020) Vol. 31, Iss. 1, pp. 12-39
Open Access | Times Cited: 1380

Showing 1-25 of 1380 citing articles:

FIGO staging of endometrial cancer: 2023
Jonathan S. Berek, Xavier Matías‐Guiu, Carien L. Creutzberg, et al.
International Journal of Gynecology & Obstetrics (2023) Vol. 162, Iss. 2, pp. 383-394
Open Access | Times Cited: 500
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer
Mansoor Raza Mirza, Dana M. Chase, Brian M. Slomovitz, et al.
New England Journal of Medicine (2023) Vol. 388, Iss. 23, pp. 2145-2158
Open Access | Times Cited: 489
Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer
Vicky Makker, Nicoletta Colombo, Antonio Casado, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 5, pp. 437-448
Open Access | Times Cited: 324
Cancer of the corpus uteri: 2021 update
Martin Koskas, Frédéric Amant, Mansoor Raza Mirza, et al.
International Journal of Gynecology & Obstetrics (2021) Vol. 155, Iss. S1, pp. 45-60
Open Access | Times Cited: 233
The TCGA Molecular Classification of Endometrial Cancer and Its Possible Impact on Adjuvant Treatment Decisions
Matthias Alexa, Annette Hasenburg, Marco Johannes Battista
Cancers (2021) Vol. 13, Iss. 6, pp. 1478-1478
Open Access | Times Cited: 138
FIGO staging of endometrial cancer: 2023
Jonathan S. Berek, Xavier Matías‐Guiu, Carien L. Creutzberg, et al.
Journal of Gynecologic Oncology (2023) Vol. 34, Iss. 5
Open Access | Times Cited: 131
Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program

International Journal of Gynecological Cancer (2022) Vol. 33, Iss. 1, pp. 109-117
Open Access | Times Cited: 108
p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial
Lisa Vermij, Alicia León‐Castillo, Naveena Singh, et al.
Modern Pathology (2022) Vol. 35, Iss. 10, pp. 1475-1483
Open Access | Times Cited: 97
Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry
Lisa Vermij, Jan J. Jobsen, Alicia León‐Castillo, et al.
British Journal of Cancer (2023) Vol. 128, Iss. 7, pp. 1360-1368
Open Access | Times Cited: 87
Prognostic relevance of the molecular classification in high-grade endometrial cancer for patients staged by lymphadenectomy and without adjuvant treatment
Alicia León‐Castillo, Nanda Horeweg, Elke E.M. Peters, et al.
Gynecologic Oncology (2022) Vol. 164, Iss. 3, pp. 577-586
Open Access | Times Cited: 76
Role of Genomic and Molecular Biology in the Modulation of the Treatment of Endometrial Cancer: Narrative Review and Perspectives
Ilaria Cuccu, Ottavia D’Oria, Ludovica Sgamba, et al.
Healthcare (2023) Vol. 11, Iss. 4, pp. 571-571
Open Access | Times Cited: 55
Novel Insights into Molecular Mechanisms of Endometrial Diseases
Tullio Golia D’Augè, Ilaria Cuccu, Giusi Santangelo, et al.
Biomolecules (2023) Vol. 13, Iss. 3, pp. 499-499
Open Access | Times Cited: 55
Management of Patients Diagnosed with Endometrial Cancer: Comparison of Guidelines
Stefano Restaino, Chiara Paglietti, Martina Arcieri, et al.
Cancers (2023) Vol. 15, Iss. 4, pp. 1091-1091
Open Access | Times Cited: 54
Grade and Estrogen Receptor Expression Identify a Subset of No Specific Molecular Profile Endometrial Carcinomas at a Very Low Risk of Disease-Specific Death
Amy Jamieson, Jutta Huvila, Derek S. Chiu, et al.
Modern Pathology (2023) Vol. 36, Iss. 4, pp. 100085-100085
Open Access | Times Cited: 53
Molecular Classification Predicts Response to Radiotherapy in the Randomized PORTEC-1 and PORTEC-2 Trials for Early-Stage Endometrioid Endometrial Cancer
Nanda Horeweg, Remi A. Nout, Ina M. Jürgenliemk‐Schulz, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 27, pp. 4369-4380
Open Access | Times Cited: 50
FIGO 2023 endometrial cancer staging: too much, too soon?
W. Glenn McCluggage, Tjalling Bosse, C. Blake Gilks, et al.
International Journal of Gynecological Cancer (2023) Vol. 34, Iss. 1, pp. 138-143
Open Access | Times Cited: 43
ENGOT-en11/GOG-3053/KEYNOTE-B21: A Randomised, Double-Blind, Phase 3 Study of Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy in Patients With Newly Diagnosed, High-Risk Endometrial Cancer
Toon Van Gorp, David Cibula, Weiguo Lv, et al.
Annals of Oncology (2024) Vol. 35, Iss. 11, pp. 968-980
Closed Access | Times Cited: 26
Sentinel node mapping in high-intermediate and high-risk endometrial cancer: Analysis of 5-year oncologic outcomes
Ilaria Cuccu, Francesco Raspagliesi, Mario Malzoni, et al.
European Journal of Surgical Oncology (2024) Vol. 50, Iss. 4, pp. 108018-108018
Closed Access | Times Cited: 20
Endometrial Stem Cells: Orchestrating Dynamic Regeneration of Endometrium and Their Implications in Diverse Endometrial Disorders
In‐Sun Hong
International Journal of Biological Sciences (2024) Vol. 20, Iss. 3, pp. 864-879
Open Access | Times Cited: 19
Prediction of recurrence risk in endometrial cancer with multimodal deep learning
Sarah Volinsky-Fremond, Nanda Horeweg, Sonali Andani, et al.
Nature Medicine (2024) Vol. 30, Iss. 7, pp. 1962-1973
Open Access | Times Cited: 19
Mismatch Repair Deficiency as a Predictive and Prognostic Biomarker in Endometrial Cancer: A Review on Immunohistochemistry Staining Patterns and Clinical Implications
Francesca Addante, Antonio d’Amati, Angela Santoro, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 1056-1056
Open Access | Times Cited: 17
Oncologic outcomes based on lymphovascular space invasion in node-negative FIGO 2009 stage I endometrioid endometrial adenocarcinoma: a multicenter retrospective cohort study
Christian Dagher, Pernille Bjerre Trent, Rofieda Alwaqfi, et al.
International Journal of Gynecological Cancer (2024) Vol. 34, Iss. 10, pp. 1485-1492
Closed Access | Times Cited: 17
The prognostic impact of molecular classification in endometrial cancer that undergoes fertility-sparing treatment
Luigi Antonio De Vitis, Gabriella Schivardi, Susanna Delfrati, et al.
International Journal of Gynecological Cancer (2025) Vol. 35, Iss. 1, pp. 100024-100024
Closed Access | Times Cited: 3
FIGO 2023 staging system predicts not only survival outcome but also recurrence pattern in corpus-confined endometrial cancer patients
Hua-Hsi Wu, Hung-Tse Chou, Shih-Yao Lin, et al.
Taiwanese Journal of Obstetrics and Gynecology (2025) Vol. 64, Iss. 1, pp. 76-81
Open Access | Times Cited: 3
The prognostic and clinical significance of substantial lymphovascular space invasion in early-stage endometrial carcinoma
Zhuang Li, Jiali Peng, Bingxin Zhang, et al.
European Journal of Cancer (2025), pp. 115258-115258
Closed Access | Times Cited: 2
Page 1 - Next Page

Scroll to top